|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FTL |
Gene summary for FTL |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FTL | Gene ID | 2512 |
| Gene name | ferritin light chain | |
| Gene Alias | LFTD | |
| Cytomap | 19q13.33 | |
| Gene Type | protein-coding | GO ID | GO:0000041 | UniProtAcc | P02792 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2512 | FTL | HTA11_5212_2000001011 | Human | Colorectum | AD | 6.80e-26 | 1.65e+00 | -0.2061 |
| 2512 | FTL | HTA11_5216_2000001011 | Human | Colorectum | SER | 1.11e-15 | 1.61e+00 | -0.1462 |
| 2512 | FTL | HTA11_546_2000001011 | Human | Colorectum | AD | 3.38e-45 | 2.09e+00 | -0.0842 |
| 2512 | FTL | HTA11_9341_2000001011 | Human | Colorectum | SER | 3.40e-10 | 1.23e+00 | -0.00410000000000005 |
| 2512 | FTL | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.41e-09 | 7.90e-01 | -0.0179 |
| 2512 | FTL | HTA11_866_3004761011 | Human | Colorectum | AD | 2.54e-85 | 2.22e+00 | 0.096 |
| 2512 | FTL | HTA11_4255_2000001011 | Human | Colorectum | SER | 5.46e-22 | 1.80e+00 | 0.0446 |
| 2512 | FTL | HTA11_9408_2000001011 | Human | Colorectum | AD | 7.35e-24 | 2.15e+00 | 0.0451 |
| 2512 | FTL | HTA11_8622_2000001021 | Human | Colorectum | SER | 1.33e-25 | 1.72e+00 | 0.0528 |
| 2512 | FTL | HTA11_7663_2000001011 | Human | Colorectum | SER | 6.19e-21 | 1.93e+00 | 0.0131 |
| 2512 | FTL | HTA11_10623_2000001011 | Human | Colorectum | AD | 5.85e-25 | 1.98e+00 | -0.0177 |
| 2512 | FTL | HTA11_6801_2000001011 | Human | Colorectum | SER | 9.95e-23 | 2.36e+00 | 0.0171 |
| 2512 | FTL | HTA11_10711_2000001011 | Human | Colorectum | AD | 4.55e-49 | 2.08e+00 | 0.0338 |
| 2512 | FTL | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.60e-94 | 2.40e+00 | 0.0674 |
| 2512 | FTL | HTA11_6818_2000001011 | Human | Colorectum | AD | 3.38e-29 | 2.26e+00 | 0.0112 |
| 2512 | FTL | HTA11_7469_2000001011 | Human | Colorectum | AD | 1.95e-17 | 1.66e+00 | -0.0124 |
| 2512 | FTL | HTA11_11156_2000001011 | Human | Colorectum | AD | 1.68e-16 | 1.73e+00 | 0.0397 |
| 2512 | FTL | HTA11_6818_2000001021 | Human | Colorectum | AD | 7.81e-46 | 1.80e+00 | 0.0588 |
| 2512 | FTL | HTA11_99999970781_79442 | Human | Colorectum | MSS | 9.60e-56 | 1.49e+00 | 0.294 |
| 2512 | FTL | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 3.70e-17 | 2.38e+00 | 0.3487 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00512358 | Breast | Precancer | maintenance of location | 40/1080 | 327/18723 | 5.85e-06 | 1.71e-04 | 40 |
| GO:00516519 | Breast | Precancer | maintenance of location in cell | 30/1080 | 214/18723 | 5.91e-06 | 1.71e-04 | 30 |
| GO:00512383 | Breast | Precancer | sequestering of metal ion | 7/1080 | 16/18723 | 1.50e-05 | 3.71e-04 | 7 |
| GO:00550767 | Breast | Precancer | transition metal ion homeostasis | 20/1080 | 138/18723 | 1.28e-04 | 2.24e-03 | 20 |
| GO:00469165 | Breast | Precancer | cellular transition metal ion homeostasis | 17/1080 | 115/18723 | 3.15e-04 | 4.49e-03 | 17 |
| GO:00550725 | Breast | Precancer | iron ion homeostasis | 12/1080 | 85/18723 | 3.41e-03 | 2.85e-02 | 12 |
| GO:00068263 | Breast | Precancer | iron ion transport | 9/1080 | 58/18723 | 5.67e-03 | 4.08e-02 | 9 |
| GO:00000412 | Breast | Precancer | transition metal ion transport | 13/1080 | 105/18723 | 7.35e-03 | 4.89e-02 | 13 |
| GO:005165114 | Breast | IDC | maintenance of location in cell | 37/1434 | 214/18723 | 2.39e-06 | 9.35e-05 | 37 |
| GO:005123513 | Breast | IDC | maintenance of location | 48/1434 | 327/18723 | 9.90e-06 | 2.77e-04 | 48 |
| GO:005123811 | Breast | IDC | sequestering of metal ion | 7/1434 | 16/18723 | 9.40e-05 | 1.81e-03 | 7 |
| GO:005507613 | Breast | IDC | transition metal ion homeostasis | 23/1434 | 138/18723 | 3.20e-04 | 4.79e-03 | 23 |
| GO:004691612 | Breast | IDC | cellular transition metal ion homeostasis | 20/1434 | 115/18723 | 4.35e-04 | 5.90e-03 | 20 |
| GO:000682611 | Breast | IDC | iron ion transport | 11/1434 | 58/18723 | 4.10e-03 | 3.25e-02 | 11 |
| GO:005507212 | Breast | IDC | iron ion homeostasis | 14/1434 | 85/18723 | 4.98e-03 | 3.77e-02 | 14 |
| GO:005165123 | Breast | DCIS | maintenance of location in cell | 36/1390 | 214/18723 | 3.07e-06 | 1.02e-04 | 36 |
| GO:005123523 | Breast | DCIS | maintenance of location | 47/1390 | 327/18723 | 9.55e-06 | 2.56e-04 | 47 |
| GO:00512382 | Breast | DCIS | sequestering of metal ion | 7/1390 | 16/18723 | 7.70e-05 | 1.48e-03 | 7 |
| GO:005507622 | Breast | DCIS | transition metal ion homeostasis | 23/1390 | 138/18723 | 2.04e-04 | 3.27e-03 | 23 |
| GO:004691621 | Breast | DCIS | cellular transition metal ion homeostasis | 20/1390 | 115/18723 | 2.91e-04 | 4.27e-03 | 20 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0421610 | Breast | Precancer | Ferroptosis | 11/684 | 41/8465 | 2.95e-04 | 2.45e-03 | 1.88e-03 | 11 |
| hsa0421613 | Breast | Precancer | Ferroptosis | 11/684 | 41/8465 | 2.95e-04 | 2.45e-03 | 1.88e-03 | 11 |
| hsa0421623 | Breast | IDC | Ferroptosis | 12/867 | 41/8465 | 5.87e-04 | 4.89e-03 | 3.66e-03 | 12 |
| hsa0497812 | Breast | IDC | Mineral absorption | 13/867 | 60/8465 | 6.73e-03 | 3.42e-02 | 2.56e-02 | 13 |
| hsa0421633 | Breast | IDC | Ferroptosis | 12/867 | 41/8465 | 5.87e-04 | 4.89e-03 | 3.66e-03 | 12 |
| hsa0497813 | Breast | IDC | Mineral absorption | 13/867 | 60/8465 | 6.73e-03 | 3.42e-02 | 2.56e-02 | 13 |
| hsa0421642 | Breast | DCIS | Ferroptosis | 12/846 | 41/8465 | 4.69e-04 | 3.69e-03 | 2.72e-03 | 12 |
| hsa0497821 | Breast | DCIS | Mineral absorption | 13/846 | 60/8465 | 5.48e-03 | 2.81e-02 | 2.07e-02 | 13 |
| hsa0421652 | Breast | DCIS | Ferroptosis | 12/846 | 41/8465 | 4.69e-04 | 3.69e-03 | 2.72e-03 | 12 |
| hsa0497831 | Breast | DCIS | Mineral absorption | 13/846 | 60/8465 | 5.48e-03 | 2.81e-02 | 2.07e-02 | 13 |
| hsa0421614 | Cervix | CC | Ferroptosis | 14/1267 | 41/8465 | 1.75e-03 | 7.21e-03 | 4.26e-03 | 14 |
| hsa0421615 | Cervix | CC | Ferroptosis | 14/1267 | 41/8465 | 1.75e-03 | 7.21e-03 | 4.26e-03 | 14 |
| hsa0421624 | Cervix | N_HPV | Ferroptosis | 6/349 | 41/8465 | 6.24e-03 | 3.24e-02 | 2.54e-02 | 6 |
| hsa0421634 | Cervix | N_HPV | Ferroptosis | 6/349 | 41/8465 | 6.24e-03 | 3.24e-02 | 2.54e-02 | 6 |
| hsa04216 | Colorectum | AD | Ferroptosis | 21/2092 | 41/8465 | 2.23e-04 | 1.78e-03 | 1.13e-03 | 21 |
| hsa042161 | Colorectum | AD | Ferroptosis | 21/2092 | 41/8465 | 2.23e-04 | 1.78e-03 | 1.13e-03 | 21 |
| hsa04217 | Colorectum | SER | Necroptosis | 47/1580 | 159/8465 | 5.21e-04 | 4.44e-03 | 3.22e-03 | 47 |
| hsa042171 | Colorectum | SER | Necroptosis | 47/1580 | 159/8465 | 5.21e-04 | 4.44e-03 | 3.22e-03 | 47 |
| hsa042162 | Colorectum | MSS | Ferroptosis | 18/1875 | 41/8465 | 1.53e-03 | 8.53e-03 | 5.23e-03 | 18 |
| hsa042163 | Colorectum | MSS | Ferroptosis | 18/1875 | 41/8465 | 1.53e-03 | 8.53e-03 | 5.23e-03 | 18 |
| Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FTL | SNV | Missense_Mutation | c.382N>A | p.Asp128Asn | p.D128N | P02792 | protein_coding | deleterious(0.03) | possibly_damaging(0.722) | TCGA-E2-A1B5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| FTL | SNV | Missense_Mutation | novel | c.383N>G | p.Asp128Gly | p.D128G | P02792 | protein_coding | deleterious(0.02) | possibly_damaging(0.792) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| FTL | SNV | Missense_Mutation | c.31N>G | p.Thr11Ala | p.T11A | P02792 | protein_coding | tolerated(0.5) | benign(0.007) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| FTL | SNV | Missense_Mutation | rs559631027 | c.265N>A | p.Glu89Lys | p.E89K | P02792 | protein_coding | deleterious(0.04) | possibly_damaging(0.463) | TCGA-HM-A3JJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| FTL | SNV | Missense_Mutation | rs770196454 | c.247A>G | p.Lys83Glu | p.K83E | P02792 | protein_coding | tolerated(0.05) | benign(0) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| FTL | SNV | Missense_Mutation | novel | c.502G>A | p.Glu168Lys | p.E168K | P02792 | protein_coding | tolerated(0.18) | benign(0.276) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| FTL | SNV | Missense_Mutation | novel | c.174G>T | p.Glu58Asp | p.E58D | P02792 | protein_coding | deleterious(0.01) | benign(0.047) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| FTL | insertion | Frame_Shift_Ins | novel | c.422_423insTATCA | p.Lys143IlefsTer9 | p.K143Ifs*9 | P02792 | protein_coding | TCGA-G4-6315-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | SD | ||
| FTL | SNV | Missense_Mutation | novel | c.512N>T | p.Thr171Ile | p.T171I | P02792 | protein_coding | deleterious(0.02) | benign(0.104) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FTL | SNV | Missense_Mutation | novel | c.320N>C | p.Leu107Pro | p.L107P | P02792 | protein_coding | deleterious(0.03) | possibly_damaging(0.495) | TCGA-AJ-A3NE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |